What Happened
Janice Mae Brown, 39, of Russell, Kansas, was indicted by a federal grand jury in Wichita on January 29, 2026 on one count of acquiring a controlled substance by deception and subterfuge.
According to the indictment, Brown used her position as a pharmacy technician to remove amphetamine (Adderall) and methylphenidate (Ritalin) from her employer's pharmacy inventory without authorization. The theft of stimulants by a technician is notable because it required working around pharmacist oversight and inventory controls that should sit between a technician and finished Schedule II stock.
The charge — acquiring a controlled substance by deception and subterfuge — is the standard federal charge for pharmacy insiders who take product outside a legitimate dispensing pathway. The case remains pending, and Brown is presumed innocent unless and until proven guilty.
What Went Wrong
The public record does not describe the pharmacy's internal controls, so the analysis below is hypothesis based on the pattern alleged. A technician typically has no legitimate need to possess Schedule II product outside the pharmacist's direct line of sight, so removal implies oversight gaps. Technician-level diversion typically points to:
- Technician access to Schedule II stock beyond what the job requires, with no independent verification of stock movements.
- Inventory counts that did not catch the shrinkage, or counts performed predictably enough to be worked around.
- No transaction-level review of who accessed controlled substance inventory and when, so the removals left no examined audit trail.
- Insufficient pharmacist oversight of technician handling of high-risk products, including counts and stocking activities.
- Red-flag monitoring applied to customers rather than to employees, who know the count schedule and how to avoid triggering alerts.
- No independent check that controlled substance removals were limited to employees whose duties required access at that time.
How It Could Have Been Prevented
- Enforce role-based access so technicians can only handle controlled substances under direct pharmacist observation, with independent verification of all stock movements.
- Reconcile Schedule II purchases, dispensing and physical inventory at least weekly, investigating every variance.
- Run randomized, unannounced cycle counts of high-risk stimulants so audit timing cannot be predicted.
- Review transaction logs for employee-linked activity and investigate any controlled substance movement without a corresponding prescription.
- Train all pharmacy staff on the red flags of diversion and publicize a confidential reporting pathway.
- Conduct a documented monthly review of employee access logs and controlled substance transactions, and retain the review.
Related Guidance
- Corresponding Responsibility Guide — The pharmacist's legal duty to ensure every controlled substance order is issued for a legitimate medical purpose.
- 15 Red Flags of Drug Diversion — Behavioral and recordkeeping indicators of diversion by pharmacy staff.
- Hospital Self-Assessment Checklist — Hospital self-assessment, 8 sections and 63 weighted items.
- Controlled Substance Inventory Guide — Biennial inventory requirements and perpetual count best practices.
- Employee Screening & Fitness for Duty — DEA screening requirements (21 C.F.R. §1301.90) and pre-employment vetting for staff with controlled substance access.